TY - JOUR
T1 - Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
AU - Lubich, Christian
AU - Steinitz, Katharina Nora
AU - Hoelbl, Brigitte
AU - Prenninger, Thomas
AU - van Helden, Pauline Maria
AU - Weiller, Markus
AU - Reipert, Birgit Maria
N1 - Funding Information:
The authors declare that this study received funding from Baxalta Innovations GmbH. The funder had the following involvement in the study: study design, interpretation of data, writing of this article and the decision to submit it for publication.
Publisher Copyright:
Copyright © 2022 Lubich, Steinitz, Hoelbl, Prenninger, van Helden, Weiller and Reipert.
PY - 2022/10/21
Y1 - 2022/10/21
N2 - BACKGROUND AND AIMS: Hemophilia A is a severe bleeding disorder caused by the deficiency of functionally active coagulation factor VIII (FVIII). The induction of neutralizing anti-drug antibodies is a major complication in the treatment of hemophilia A patients with FVIII replacement therapies. Why some patients develop neutralizing antibodies (FVIII inhibitors) while others do not is not well understood. Previous studies indicated that the induction of FVIII inhibitors requires cognate interactions between FVIII-specific B cells and FVIII-specific CD4+ T cells in germinal center reactions. In this study, we investigated the FVIII peptide repertoire presented by antigen-presenting cells (APCs) under different microenvironment conditions that are expected to alter the uptake of FVIII by APCs. The aim of this study was to better understand the association between different microenvironment conditions during FVIII uptake and the FVIII peptide patterns presented by APCs.METHODS: We used a FVIII-specific CD4+ T cell hybridoma library derived from humanized HLA-DRB1*1501 (human MHC class II) hemophilic mice that were treated with human FVIII. APCs obtained from the same mouse strain were preincubated with FVIII under different conditions which are expected to alter the uptake of FVIII by APCs. Subsequently, these preincubated APCs were used to stimulate the FVIII-specific CD4+ T cell hybridoma library. Stimulation of peptide-specific CD4+ T-cell hybridoma clones was assessed by analyzing the IL-2 release into cell culture supernatants.RESULTS: The results of this study indicate that the specific microenvironment conditions during FVIII uptake by APCs determine the peptide specificities of subsequently activated FVIII-specific CD4+ T cell hybridoma clones. Incubation of APCs with FVIII complexed with von Willebrand Factor, FVIII activated by thrombin or FVIII combined with a blockade of receptors on APCs previously associated with FVIII uptake and clearance, resulted in distinct peptide repertoires of subsequently activated hybridoma clones.CONCLUSION: Based on our data we conclude that the specific microenvironment during FVIII uptake by APCs determines the FVIII peptide repertoire presented on MHC class II expressed by APCs and the peptide specificity of subsequently activated FVIII-specific CD4+ T cell hybridoma clones.
AB - BACKGROUND AND AIMS: Hemophilia A is a severe bleeding disorder caused by the deficiency of functionally active coagulation factor VIII (FVIII). The induction of neutralizing anti-drug antibodies is a major complication in the treatment of hemophilia A patients with FVIII replacement therapies. Why some patients develop neutralizing antibodies (FVIII inhibitors) while others do not is not well understood. Previous studies indicated that the induction of FVIII inhibitors requires cognate interactions between FVIII-specific B cells and FVIII-specific CD4+ T cells in germinal center reactions. In this study, we investigated the FVIII peptide repertoire presented by antigen-presenting cells (APCs) under different microenvironment conditions that are expected to alter the uptake of FVIII by APCs. The aim of this study was to better understand the association between different microenvironment conditions during FVIII uptake and the FVIII peptide patterns presented by APCs.METHODS: We used a FVIII-specific CD4+ T cell hybridoma library derived from humanized HLA-DRB1*1501 (human MHC class II) hemophilic mice that were treated with human FVIII. APCs obtained from the same mouse strain were preincubated with FVIII under different conditions which are expected to alter the uptake of FVIII by APCs. Subsequently, these preincubated APCs were used to stimulate the FVIII-specific CD4+ T cell hybridoma library. Stimulation of peptide-specific CD4+ T-cell hybridoma clones was assessed by analyzing the IL-2 release into cell culture supernatants.RESULTS: The results of this study indicate that the specific microenvironment conditions during FVIII uptake by APCs determine the peptide specificities of subsequently activated FVIII-specific CD4+ T cell hybridoma clones. Incubation of APCs with FVIII complexed with von Willebrand Factor, FVIII activated by thrombin or FVIII combined with a blockade of receptors on APCs previously associated with FVIII uptake and clearance, resulted in distinct peptide repertoires of subsequently activated hybridoma clones.CONCLUSION: Based on our data we conclude that the specific microenvironment during FVIII uptake by APCs determines the FVIII peptide repertoire presented on MHC class II expressed by APCs and the peptide specificity of subsequently activated FVIII-specific CD4+ T cell hybridoma clones.
KW - Humans
KW - Mice
KW - Animals
KW - Factor VIII
KW - Hemophilia A/drug therapy
KW - CD4-Positive T-Lymphocytes
KW - Antigen-Presenting Cells
KW - Hemostatics
KW - Peptides
KW - FVIII-specific CD4+ T-cell hybridoma library
KW - FVIII presentation by antigen-presenting cells
KW - FVIII inhibitors
KW - Hemophilia A
KW - microenvironment during FVIII uptake by antigen-presenting cells
KW - neutralizing anti-drug antibodies
KW - HLA-DRB11501 humanized hemophilic mice
UR - http://www.scopus.com/inward/record.url?scp=85141623781&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.975680
DO - 10.3389/fimmu.2022.975680
M3 - Article
C2 - 36389737
SN - 1664-3224
VL - 13
SP - 975680
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 975680
ER -